GILD financials
Gilead Sciences, Inc. · end-of-day data as of Oct 16, 2026
Gilead Sciences, Inc.
$156.19+21.5%
Buy · 28 analystsPT $159.20 +1.9%
GILD reported revenue of $7.8B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 10.2% from a year earlier. It posted diluted EPS of -$8.45, free cash flow of $3.69B and a net margin of -134.5%.
Valuation
- P/E—
- P/E vs own—
- P/E vs sector—
- FCF yield+6.8%
- Market cap$194B
Quarterly results
Q2 FY2026: Revenue +10.2% year over year, free cash flow 47.3% of revenue, operating margin -133.2%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $7.8B | -8.45 | $3.69B | 79.8% | -133.2% | -134.5% |
| Q1 FY2026 | Mar 31, 2026 | $6.96B | 1.61 | $2.43B | 79.2% | 37.2% | 29.0% |
| Q4 FY2025 | Dec 31, 2025 | $7.92B | 1.74 | $3.12B | 79.5% | 37.7% | 27.5% |
| Q3 FY2025 | Sep 30, 2025 | $7.77B | 2.43 | $3.96B | 79.8% | 42.8% | 39.3% |
| Q2 FY2025 | Jun 30, 2025 | $7.08B | 1.56 | $720M | 78.8% | 34.9% | 27.7% |
| Q1 FY2025 | Mar 31, 2025 | $6.67B | 1.04 | $1.65B | 76.9% | 33.6% | 19.7% |
| Q4 FY2024 | Dec 31, 2024 | $7.57B | 1.42 | $2.83B | 79.1% | 32.4% | 23.6% |
| Q3 FY2024 | Sep 30, 2024 | $7.54B | 1.00 | $4.17B | 79.1% | 11.8% | 16.6% |
| Q2 FY2024 | Jun 30, 2024 | $6.95B | 1.29 | $1.2B | 77.8% | 38.0% | 23.2% |
| Q1 FY2024 | Mar 31, 2024 | $6.69B | -3.34 | $2.11B | 76.8% | -64.6% | -62.4% |
| Q4 FY2023 | Dec 31, 2023 | $7.11B | 1.14 | $1.95B | 70.6% | 22.7% | 20.1% |
| Q3 FY2023 | Sep 30, 2023 | $7.05B | 1.73 | $1.63B | 77.8% | 37.2% | 30.9% |